{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:50:07Z","timestamp":1789678207812,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The effects of corticosteroid use on the reactogenicity and immunogenicity of ChAdOx1 nCoV-19 (ChAd) vaccine were evaluated. Healthcare workers (HCWs) who took low-dose corticosteroid agents around the time of the first dose of ChAd (ChAdPd group) were recruited and the reactogenicity and immunogenicity were compared with those of ChAd (ChAd group) and BNT162b2 vaccination (BNT group) of HCWs without corticosteroid exposure. The immunogenicity was measured three weeks after vaccination using quantitative anti-SARS-CoV-2 spike protein (S) antibody electrochemiluminescence immunoassay and interferon gamma (IFN-\u03b3) release assay. A total of 67 HCWs comprising 24 ChAd, 29 BNT, and 14 ChAdPd was included. The median total corticosteroid dose of the ChAdPd group was 30 mg prednisolone equivalents (interquartile range (IQR) 20\u201371.3 mg). HCWs in the ChAdPd group experienced significantly milder reactogenicity (median total score 7.5, IQR 4.0\u201318.0) compared to those in the ChAd group (median 23.0, IQR 8.0\u201343.0,<jats:italic>P<\/jats:italic>=0.012) but similar to that in the BNT group (median 5.0, IQR 3.0\u20139.0,<jats:italic>P<\/jats:italic>=0.067). The S antibody concentration of the ChAdPd group (62.4 \u00b1 70.0 U\/mL) was higher than that of the ChAd group, though without statistical significance (3.45 \u00b1 57.6 U\/mL,<jats:italic>P<\/jats:italic>=0.192). The cellular immune response was most robust in the ChAdPd group, with significantly higher IFN-\u03b3 concentration (5.363 \u00b1 4.276 IU\/mL), compared to the ChAd (0.978 \u00b1 1.181 IU\/mL,<jats:italic>P<\/jats:italic>=0.002) and BNT (1.656 \u00b1 1.925 IU\/mL,<jats:italic>P<\/jats:italic>=0.009) groups. This finding suggest that short-term corticosteroid reduces reactogenicity of the first dose of ChAd without hindering immunogenicity.<\/jats:p>","DOI":"10.3389\/fimmu.2021.744206","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:38:08Z","timestamp":1632289088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine"],"prefix":"10.3389","volume":"12","author":[{"given":"Jinyoung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Yang","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beomki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol-In","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Ryeon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yae-Jean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong Ran","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B3","unstructured":"EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU, News 29\/01\/2021"},{"key":"B4","unstructured":"EMA Recommends First COVID-19 Vaccine for Authorisation in the EU, News 21\/12\/2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","article-title":"Adverse Events in Healthcare Workers After the First Dose of ChAdOx1 Ncov-19 or BNT162b2 mRNA COVID-19 Vaccination: A Single Center Experience","volume":"36","author":"Kim","year":"2021","journal-title":"J Korean Med Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse Reactions Following the First Dose of ChAdOx1 Ncov-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea","volume":"36","author":"Bae","year":"2021","journal-title":"J Korean Med Sci"},{"key":"B7","unstructured":"Considerations for Taking Medication Before Getting Vaccinated"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3346\/jkms.2021.36.e95","article-title":"COVID-19 Vaccination in Patients With Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology","volume":"36","author":"Park","year":"2021","journal-title":"J Korean Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low Immunogenicity to SARS-CoV-2 Vaccination Among Liver Transplant Recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01694-20","article-title":"Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2","volume":"58","author":"Muench","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B11","unstructured":"Elecsys Anti-SARS-CoV-2-S Assay Method Sheet"},{"key":"B12","unstructured":"Elecsys Anti-SARS-CoV-2-S Assay Fact Sheet"},{"key":"B13","unstructured":"Tracking SARS-CoV-2 Variants"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/jcm10071376","article-title":"Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium Tuberculosis Infections in Tertiary Care Setting","volume":"10","author":"Jung","year":"2021","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-Specific Cell-Mediated Immunity With a Commercial ELISA-Based Interferon-\u03b3 Release Assay in Kidney Transplant Recipients Treated With Antithymocyte Globulin","volume":"20","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","unstructured":"Restart of AstraZeneca Vaccination From 12 April"},{"key":"B19","doi-asserted-by":"publisher","first-page":"j3887","DOI":"10.1136\/bmj.j3887","article-title":"Corticosteroids for Treatment of Sore Throat: Systematic Review and Meta-Analysis of Randomised Trials","volume":"358","author":"Sadeghirad","year":"2017","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","article-title":"Pneumococcal Polysaccharide Vaccination in Adults Undergoing Immunosuppressive Treatment for Inflammatory Diseases\u2013a Longitudinal Study","volume":"17","author":"Fischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.004","article-title":"Hepatitis B Virus Vaccination in Children With Steroid Sensitive Nephrotic Syndrome: Immunogenicity and Safety","volume":"31","author":"Y\u0131ld\u0131z","year":"2013","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.152.12.1191","article-title":"Effect of Prednisone on Response to Influenza Virus Vaccine in Asthmatic Children","volume":"152","author":"Fairchok","year":"1998","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1542\/peds.98.2.196","article-title":"Influenza Vaccination of Children During Acute Asthma Exacerbation and Concurrent Prednisone Therapy","volume":"98","author":"Park","year":"1996","journal-title":"Pediatrics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.06.006","article-title":"Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening","volume":"22","author":"Nace","year":"2021","journal-title":"J Am Med Directors Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0282","article-title":"Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/gt.2008.18","article-title":"Wild-Type Adenoviruses From Groups A-F Evoke Unique Innate Immune Responses, of Which HAd3 and SAd23 Are Partially Complement Dependent","volume":"15","author":"Appledorn","year":"2008","journal-title":"Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.297","article-title":"Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing Efficacy","volume":"17","author":"Seregin","year":"2009","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1211","article-title":"Interferon-\u03b3 Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice","volume":"71","author":"Kim","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2020.12.002","article-title":"PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, But Functional in Patients With COVID-19","volume":"54","author":"Rha","year":"2021","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.744206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T22:18:31Z","timestamp":1673302711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.744206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2021.744206"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.744206","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"744206"}}